| Literature DB >> 32718500 |
Zachary Winder1, Donna Wilcock1, Gregory A Jicha2.
Abstract
This article focuses on current clinical laboratory testing to diagnose Alzheimer disease and monitor its progression throughout its disease course. Several clinically available tests focus on analysis of amyloid and tau levels in cerebrospinal fluid as well as autosomal dominant and risk factor genes. Although the current armament of clinical laboratory testing is limited by invasiveness of cerebrospinal fluid collection, rarity of autosomal dominant genetic mutations, and uncertainties of risk inherent in nonpenetrant genes, the field is poised to advance the clinical repertoire of laboratory diagnostic testing.Entities:
Keywords: Alzheimer’s disease; Cerebrospinal fluid (CSF); Mild cognitive impairment (MCI); Phospho-tau; Preclinical AD; Tau; β-amyloid (Aβ)
Mesh:
Substances:
Year: 2020 PMID: 32718500 DOI: 10.1016/j.cll.2020.05.003
Source DB: PubMed Journal: Clin Lab Med ISSN: 0272-2712 Impact factor: 1.935